These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36641325)

  • 41. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
    Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
    Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
    Yamashita Y; Kataoka K; Ishida T; Matsuura M; Seno N; Mukaida H; Miyahara E; Miyata Y; Okita R; Shimizu K; Watari M; Okumichi T; Okada M
    J Thorac Oncol; 2008 Jun; 3(6):612-6. PubMed ID: 18520800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer.
    Naim Younes R; Gross JL; Abrao FG; Rodrigues Pereira J
    Minerva Chir; 2013 Apr; 68(2):169-74. PubMed ID: 23612230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.
    Williams CD; Gajra A; Ganti AK; Kelley MJ
    Cancer; 2014 Jul; 120(13):1939-47. PubMed ID: 24668613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
    Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
    Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Tada H; Kajiwara S; Watanabe N; Okada M; Sakamoto J; Aoe M; Soh J; Miyoshi S; Hotta K; Matsuo K; Date H
    J Thorac Oncol; 2018 May; 13(5):699-706. PubMed ID: 29505900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.
    Okumura N; Sonobe M; Okabe K; Nakamura H; Kataoka M; Yamashita M; Nakata M; Kataoka K; Yamashita Y; Soh J; Yoshioka H; Hotta K; Matsuo K; Sakamoto J; Toyooka S; Date H
    Int J Clin Oncol; 2017 Apr; 22(2):274-282. PubMed ID: 27921177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
    Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
    Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
    Uramoto H; Nakanishi R; Nagashima A; Uchiyama A; Inoue M; Osaki T; Yoshimatsu T; Sakata H; Nakanishi K; Yasumoto K
    Anticancer Res; 2010 Nov; 30(11):4695-9. PubMed ID: 21115926
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world study of disease-free survival & patient characteristics associated with disease-free survival in early-stage non-small cell lung cancer: A retrospective observational study.
    Shah A; Apple J; Belli AJ; Barcellos A; Hansen E; Fernandes LL; Zettler CM; Wang CK
    Cancer Treat Res Commun; 2023; 36():100742. PubMed ID: 37478531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
    Sakurai R; Tomizawa Y; Yoshii A; Miura Y; Tsurumaki H; Kaira K; Sunaga N; Kawashima O; Hisada T; Yamada M; Saito R
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):103-109. PubMed ID: 29124327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
    Felip E; Rosell R; Maestre JA; Rodríguez-Paniagua JM; Morán T; Astudillo J; Alonso G; Borro JM; González-Larriba JL; Torres A; Camps C; Guijarro R; Isla D; Aguiló R; Alberola V; Padilla J; Sánchez-Palencia A; Sánchez JJ; Hermosilla E; Massuti B;
    J Clin Oncol; 2010 Jul; 28(19):3138-45. PubMed ID: 20516435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.
    Zhang P; Duan J; Bai H; Wang Z; Gao S; Tan F; Gao Y; Wang X; Wan R; Xu J; He X; Feng X; Yu R; Sun J; Zhao Z; Fei K; Li N; He J; Wang J
    Thorac Cancer; 2021 Jan; 12(1):30-39. PubMed ID: 33111432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial.
    Shen WY; Ji J; Zuo YS; Pu J; Xu YM; Zong CD; Tao GZ; Chen XF; Ji FZ; Zhou XL; Han JH; Wang CS; Yi JG; Su XL; Zhu WG
    Radiother Oncol; 2014 Jan; 110(1):120-5. PubMed ID: 24183868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
    Douillard JY; Rosell R; De Lena M; Riggi M; Hurteloup P; Mahe MA;
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):695-701. PubMed ID: 18439766
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    Tsuchiya T; Kamohara R; Muraoka M; Nagayasu T; Saeki S; Takenoyama M; Suzuki M; Inada K; Tokunaga S; Hayashi T; Urabe S; Koga T; Akamine S; Sugio K
    BMC Cancer; 2020 Dec; 20(1):1192. PubMed ID: 33276755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
    Perry MC; Kohman LJ; Bonner JA; Gu L; Wang X; Vokes EE; Green MR
    Clin Lung Cancer; 2007 Jan; 8(4):268-72. PubMed ID: 17311692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer.
    Horn L; Sandler AB; Putnam JB; Johnson DH
    J Thorac Oncol; 2007 May; 2(5):377-83. PubMed ID: 17473651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.